a HIF-2a inhibitor with best-in-class potential, in an oral plenary session by Dr. Toni K. Choueiri, Dana-Farber Cancer Institute, at the 2025 American Society of Clinical Oncology (ASCO ...

Dr Jonasch next focuses on a phase 1b study of the HIF-2 alpha inhibitor casdatifan that observed an overall response rate (ORR) in the 20%-30% range, suggesting that this investigational agent is ...

(NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today presented new data for casdatifan ...

February 15, 2025--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for ...

The FDA has approved MSD’s oral HIF-2 alpha inhibitor Welireg for a second cancer indication, relapsed or refractory advanced renal cell carcinoma (RCC), the most common form of kidney cancer.

The European Commission (EC) has conditionally approved MSD's Welireg, an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, as a single agent for the treatment of adults with von Hippel ...